616K
Patients tested annually
89K
U.S. ordering and treating providers
180K
Clinicogenomic records
3M+
Pathology images
3.6M
Patients
Oncology data solutions
Your therapy deserves data from the lab that ran the test
NeoGenomics generates and curates its own molecular data, meaning the lab that ran the test is the same lab powering your data strategy. No claims extrapolation, no aggregation lag. Just direct clinicogenomic signal, purpose-built for biopharma.
Commercialization
Act on the signal, not the lag
Real-time diagnostic signals from the lab, so your field team responds to testing behavior as it happens, not weeks later from a claims feed.
- Trigger-based alerts when an HCP orders a relevant biomarker test
- Biomarker prevalence rates by territory, tumor type, and practice setting
- Concordance analysis between test results and therapy selection
- Testing gap identification where diagnosis outpaces treatment
Medical Affairs
Generate evidence that shapes clinical practice
Multi-modal, real-world data to support publication strategy, KOL engagement, and the scientific narrative behind your diagnostic approach.
- Data to support guideline inclusion and label expansion
- Rare cohort identification across 2+ million patient profiles
- Analysis on biomarker prevalence and testing patterns to track care gaps
Research
Defend your strategy with diagnostic-grade data
Lab-confirmed molecular data to model the true burden of disease and demonstrate the value of precision testing.
- Prevalence and testing rate studies for payer submissions
- Support for companion diagnostic coverage discussions
AI/ML
Train on the robust data only NeoGenomics can generate
Your algorithm is only as good as the training data behind it. NeoGenomics provides first-party, lab-generated imaging and molecular data — annotated, de-identified, and representative of the real US oncology population.
- 3+ million digital pathology images (H&E and IHC) with matched molecular results
- Varying scanners, magnifications, and multi-site data for robust training
- Multi-modal linkage: slide images, molecular data, and IHC in one dataset
- Community-setting data from all 50 states, removing academic-center bias
- Structured and robust metadata enabling precise cohort definition and model training and benchmark validation
Resources & Publications
Explore our growing collection of oncology data and precision medicine content, including white papers, case studies, and webinars. Interested in viewing our posters and publications? Click here.
